Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNO: Anastrozole vs Tamoxifen in Early Breast Cancer
NCT00291759Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 1996
- Primary completion
- Jun 2009
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Event-Free Survival and Overall Survival. Started Jan 1996; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00291759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291759.